Sushmita Veloor, MD
Physical Medicine & Rehabilitation · Topeka, KSNPI 1154391126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 38.3% of the total. Reporting peaked in 2019 at $1,020 and has fallen 87.9% since, to $123 in 2025.
Across 85 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$689
- Kowa Pharmaceuticals America, Inc.$121
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$111
- Scilex Pharmaceuticals Inc.$109
- Ipsen Biopharmaceuticals, Inc$109
- Tersera Therapeutics LLC$83
- plus $574 from 17 others
What the payments were for
- Food & beverage$1,796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $689 |
| Kowa Pharmaceuticals America, Inc. | 1 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $111 |
| Scilex Pharmaceuticals Inc. | 7 | $109 |
| Ipsen Biopharmaceuticals, Inc | 5 | $109 |
| Tersera Therapeutics LLC | 3 | $83 |
| Pfizer | 6 | $82 |
| Amgen | 5 | $78 |
| Daiichi Sankyo Inc. | 4 | $65 |
| Medtronic(2 entities) | 2 | $59 |
| Collegium Pharmaceutical, Inc. | 3 | $40 |
| Saol Therapeutics Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Novartis | 2 | $26 |
| Sentynl Therapeutics, Inc. | 2 | $26 |
| Corium, LLC | 1 | $24 |
| EMD Serono, Inc. | 2 | $24 |
| Shionogi Inc | 1 | $18 |
| GRT US Holding, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,796 in reported general payments places this provider in the 85th percentile of 80 physical medicine & rehabilitation providers in Kansas.
See all physical medicine & rehabilitation providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 34 | $54,683 |
| PercocetOxycodone Hcl/Acetaminophen | 14 | $20,712 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $14,066 |
| Xtampza ErOxycodone Myristate | 33 | $13,327 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 657 | $12,728 |
| SavellaMilnacipran Hcl | 11 | $10,860 |
| Buprenorphine | 49 | $10,627 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 278 | $8,120 |
| MovantikNaloxegol Oxalate | 16 | $7,299 |
| OxycontinOxycodone Hcl | 26 | $6,660 |
| Pregabalin | 153 | $5,665 |
| EliquisApixaban | 17 | $5,248 |
| Gabapentin | 283 | $3,378 |
| Duloxetine Hcl | 202 | $3,134 |
| Tramadol Hcl | 411 | $3,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Savella | $689 | $65,54345 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $40 | $13,32733 claims |
| PfizerEliquis | $82 | $5,24817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 80 physical medicine & rehabilitation providers in Kansas.
Other physical medicine & rehabilitation in Topeka
- Tanner ShawTopeka$2K
- Jay JaniTopeka$1K
- Joseph SankoorikalTopeka$691
- Allison BloughTopeka$187
- Eric HansenTopeka$58
- Atul PatelOverland Park$643K
- Srinivas NalamachuOverland Park$344K
- John FanHutchinson$16K
- Daniel MokKansas City$10K
- Renjini ChandraOverland Park$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.